GOLD LEVEL SPONSORS
Royal Philips of the Netherlands is a diversified technology company, focused on improving people’s lives through meaningful innovation in the areas of Healthcare, Consumer Lifestyle and Lighting. Philip’s commitment is to deliver new healthcare and lighting technologies, as well as innovative and locally relevant consumer products that make a real difference to our customers, consumers and stakeholders across the globe.
To learn more, please visit: www.philips.com/global
SILVER LEVEL SPONSORS
Pfizer Oncology is committed to pursuing innovative treatments that have a meaningful impact on people living with cancer. Our growing pipeline of biologics, small molecules, and immunotherapies is focused on identifying and translating the best scientific breakthroughs into clinical application for patients across a diverse array of solid tumors and hematologic cancers. Today, we have 10 approved oncology medicines and 14 assets currently in clinical development. By maximizing our internal scientific resources and collaborating with other companies, government and academic institutions, as well as patients and non-profit and professional organizations, we are bringing together the brightest and most enterprising minds to take on the toughest cancers. Together we can accelerate breakthrough treatments to patients around the world and work to redefine life with cancer.
To learn more, please visit: www.Pfizer.com
Astellas Pharma Inc. is a pharmaceutical company dedicated to improving the health of people around the world through provision of innovative and reliable pharmaceuticals. The organization is committed to being a global category leader in Oncology and Urology, and has several oncology compounds in development in addition to enzalutamide.
To learn more, please visit www.astellas.com/en.
Progenics is an oncology company focused on the development and commercialization of innovative targeted medicines and artificial intelligence to find, fight and follow cancer, including: therapeutic agents designed to treat cancer (AZEDRA®, 1095, and PSMA TTC); prostate-specific membrane antigen (“PSMA”) targeted imaging agent for prostate cancer (PyL™); and imaging analysis technology (aBSI and PSMA AI). Progenics has two commercial products, AZEDRA, for the treatment of patients with unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma (rare neuroendocrine tumors of neural crest origin) who require systemic anticancer therapy; and RELISTOR® (methylnaltrexone bromide) for the treatment of opioid-induced constipation, which is partnered with Bausch Health Companies Inc.
To learn more, please visit https://www.progenics.com/.
BRONZE II LEVEL SPONSORS
Bio-Techne’s Mission is to build Epic Tools for Epic Science. We have a creative, caring team of collegues throughout the world who bring unique perspectives and talents in support of the that Mission and who embody our four key Values – Empowerment, Passion. Innovation, and Collaboration.
BRONZE LEVEL SPONSORS
Blue Earth Diagnostics is a molecular imaging diagnostics company focused on the development and commercialization of novel PET imaging agents to inform clinical management and guide care for cancer patients in areas of unmet medical need. Formed in 2014, Blue Earth Diagnostics is led by recognized experts in the clinical development and commercialization of innovative nuclear medicine products. The company’s first approved and commercially available product is Axumin® (fluciclovine F 18), a novel molecular imaging agent approved in the United States and European Union for use in PET imaging to detect and localize prostate cancer in men experiencing suspected biochemical recurrence. Blue Earth Diagnostics is funded by Syncona, an investment company listed on the London Stock Exchange (LON: SYNC).
To learn more, please visit www.blueearthdiagnostics.com.
Cellanyx has developed a powerful, first-in-class oncology phenotypic biomarker platform that combines two of the most exciting technologies in medical science: single cell analysis and machine learning/ Al. Phenotypic analysis of live cells from biopsies has transformative potential to modernize cancer pathology from the 150-year old analysis of morphology and artifacts to clear observation of cell behaviors of aggressiveness and metastatic potential. Recently, a proof-of-concept study of prostate cancer was published in Urology (Urology. 2019 Feb;124:198-206) predicted adverse pathologies with an area under the curve greater than 0.80 and also predicted Gleason pattern, stage, and adverse pathology with the same high precision.
DxTx Medical is a radiology accessories company concentrated on the development and commercialization of specialized imaging products used to help clinicians identify lesions or abnormalities in MRI scanning procedures. Newly formed this year, DxTx Medical is a new and growing medical device company operated by industry veterans who are already well versed in medical devices such as MRI coils including the Medrad® eCoil MR Endorectal coil along with prostate immobilizer, contrast injectors, MRI infusion pumps and patient monitors. DxTx Medical is a privately held company located in Pittsburgh, Pennsylvania.
To learn more, please visit www.DxTxMedical.com
Exact Imaging’s ExactVu™ 29 MHz micro-ultrasound platform provides a 300% improvement in resolution over conventional ultrasound enabling real-time targeted prostate biopsies. It is simple, affordable, and an extension of the current urological workflow. For the minority of cases where MRI might assist, the FusionVu™ micro-US/MRI fusion application operates on the same platform – – and is guided by the real-time 70 micron resolution of the ExactVu system.
To learn more, please visit http://www.exactimaging.com/
Hitachi contributes to society through the development of superior, original technology and products. Hitachi Values: Harmony, Sincerity, Pioneering Spirit. Hitachi delivers innovations that answer society’s challenges. With our talented team and proven experience in global markets, we can inspire the world.
Intuitive®, maker of the da Vinci® surgical system, was founded with a simple belief: People needing medical intervention should recover as quickly and completely as possible. We’ve dedicated two decades to pioneering an integrated family of minimally invasive, robotic-assisted platforms and services with the goal of helping doctors and hospitals deliver the best outcomes possible to those in their care. Five million da Vinci procedures. 44,000 da Vinci surgeons trained worldwide. And a passion to keep innovating.
KOELIS, The Prostate Care Company has assisted urologists and radiologists worldwide in their routine clinical practice since 2006 with superior image-guided technology. Continually developing new paradigms in prostate cancer management, the KOELIS team provides the technology and consulting which enables physicians to gain confidence and accuracy in diagnosis and targeted treatments. The Trinity® Fusion Biopsy and Treatment system offers the world’s only Organ Based Tracking (OBT) software (with 3D prostate cartography) to provide physicians with 2.3mm accuracy. KOELIS has a unique solution to support your prostate care program at every step of the process, from biopsy and active surveillance to treatment and follow-up.
Mimonic is a private cancer diagnostics company based in Sydney Australia, the company’s lead product, MiCheck®, is a novel in vitro diagnostics test for the detection of prostate cancer.
The MiCheck® test combines high sensitivity and specificity enabling a reduction in the number of men undergoing unnecessary biopsies. MiCheck®’s unique advantages also include the test’s ability to be applied across several stages of patient diagnosis and monitoring in prostate cancer. Mimonic anticipates rolling out the test in the USA in the second half of 2019.
Nanospectra Biosciences is a medical device company pioneering the patient-centric use of nanomedicine for selective thermal ablation. The company is conducting a multisite clinical trial with AuroLase, the first ultra focal therapy for prostate disease. AuroLase’s ultra focal approach maximizes treatment efficacy while minimizing side effects associated with surgery, radiation, and traditional focal therapies. Nanospectra is also engaged in exclusive commercial partnerships in dermatology and veterinary medicine.
OPKO Health, Inc., a multi-national pharmaceutical and diagnostic company, establishes industry-leading positions through discovery and development of novel technologies, including the 4Kscore test which provides an accurate and personalized measure of men’s risk for aggressive prostate cancer.
The Profound Medical team is committed to achieve a new therapeutic standard in treatment of prostate diseases. Our mission is to profoundly change the standard of care by creating an incision-free and radiation-free treatment for controlled ablation of malignant and benign prostate tissue; a tomorrow where patients have access to a safe, fast and effective treatment option, so they can quickly return to their daily lives.
Profound Medical is commercializing the TULSA-PRO®, a novel technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO® is designed to provide customizable and predictable ablation of a surgeon-defined prostate volume while actively protecting the urethra and rectum to help preserve men’s natural functional abilities. TULSA-PRO® is CE marked and commercially launched in key European and other CE mark jurisdictions. TULSA-PRO® is demonstrating to be a flexible technology in customizable prostate ablation, including intermediate stage cancer, localized radio-recurrent cancer, retention and hematuria palliation in locally advanced prostate cancer, and the transition zone in large volume BPH. In May 2019, Profound submitted a 510(k) application for premarket clearance with the FDA for TULSA-PRO®.
To learn more, visit
Imagine a world free from the fear of cancer. We do, every day. That’s why at Varian, we’re obsessed with creating simpler, more efficient, and more effective technologies to power new victories in cancer care.Varian is the long-standing global leader in comprehensive solutions for radiotherapy and radiosurgery, as well as software systems for planning treatments, managing cancer clinics, sharing knowledge, coordinating care, and using data to deliver evidence-based medicine.
Learn more at http://www.varian.com/
“Science For A Better Life”
Canon Medical Systems USA, Inc., headquartered in Tustin, Calif., markets, sells, distributes and services radiology and cardiovascular systems, including CT, MR, ultrasound, X-ray and interventional X-ray equipment. For more information, visit Canon Medical Systems’ website at https://us.medical.canon.
To improve screening and early detection of cancer and other age-related chronic diseases using the latest advances in genetics and medical imaging so people can enjoy longer, healthier lives.
As the specialty care global business unit of Sanofi, our work is focused in the areas of rare diseases, rare blood disorders, multiple sclerosis, oncology, and immunology.
SOTIO is developing innovative therapies that harness the immune system and focus primarily on immuno-oncology, effectively translating science into patient benefit.